Details

Autor(en) / Beteiligte

• Leszczenko, Patrycja
• Nowakowska, Anna M.
• Jakubowska, Justyna
• Pastorczak, Agata
• Zabczynska, Marta
• Mlynarski, Wojciech
• Baranska, Malgorzata
• Ostrowska, Kinga
• Majzner, Katarzyna

Titel

Raman spectroscopy can recognize the KMT2A rearrangement as a distinct subtype of leukemia

Ist Teil von

• Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024-06, Vol.314, p.124173, Article 124173

Ort / Verlag

England: Elsevier B.V

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• [Display omitted] •Raman spectroscopy distinguishes normal and leukemic cells.•KMT2A-r BCP-ALL blasts can be identified in a label-free way.•The 1040/1008 cm−1 ratio acts as a diagnostic marker for KMT2A-r in BCP-ALL.•Trained models can identify spectra of KMT2A-r BCP-ALL blasts. Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) are the two most common hematologic malignancies, challenging to treat and associated with high recurrence and mortality rates. This work aims to identify specific Raman biomarkers of ALL cells with the KMT2A gene rearrangement (KMT2A-r), representing a highly aggressive subtype of childhood leukemia with a poor prognosis. The proposed approach combines the sensitivity and specificity of Raman spectroscopy with machine learning and allows us to distinguish not only myelo- and lymphoblasts but also discriminate B-cell precursor (BCP) ALL with KMT2A-r from other blasts of BCP-ALL. We have found that KMT2A-r ALL cells fixed with 0.5% glutaraldehyde exhibit a unique spectroscopic profile that enables us to identify this subtype from other leukemias and normal cells. Therefore, a rapid and label-free method was developed to identify ALL blasts with KMT2A-r based on the ratio of the two Raman bands assigned to phenylalanine – 1040 and 1008 cm−1. This is the first time that a particular group of leukemic cells has been identified in a label-free way. The identified biomarker can be used as a screening method in diagnostic laboratories or non-reference medical centers.